Literature DB >> 31068503

High sex hormone-binding globulin concentration is a risk factor for high fibrosis-4 index in middle-aged Japanese men.

Yuya Fujihara1,2, Nobuya Hamanoue2, Hiromi Yano3, Makito Tanabe2, Yuko Akehi2,4, Takashi Nomiyama2, Toshihiko Yanase1,2.   

Abstract

Low endogenous testosterone and sex hormone-binding globulin (SHBG) concentrations have been reported to be associated with metabolic syndrome (MetS) and non-alcoholic fatty liver disease (NAFLD). However, little is known about the relationships between testosterone or SHBG and liver fibrosis in NAFLD. Thus, we aimed to clarify the relationships between serum testosterone or SHBG concentration and fibrosis-4 (FIB-4) index, a marker of liver fibrosis. Serum testosterone was assayed in various forms (total testosterone [TT], calculated free testosterone [cFT], calculated bioavailable testosterone [cbT], and SHBG) and metabolic markers were also measured in 363 Japanese men (mean age 51.1 ± 8.7 years) at routine health examinations. We then attempted to identify the factors contributing to liver fibrosis by investigating the associations between the metabolic markers, including testosterone, and FIB-4 index. People with a relatively high FIB-4 index (≥1.3) demonstrated lower cFT, cbT, homeostasis model assessment (HOMA)-β, low-density lipoprotein-cholesterol, and blood urea nitrogen, but higher SHBG, than those with a lower FIB-4 index (<1.3). There were no significant differences in HbA1c, fasting glucose concentration, HOMA-R, or metabolic syndrome prevalence between the two groups. Binary regression analysis revealed that SHBG ≥52 nmol/L and cFT <8.0 ng/dL were statistically significant risk factors for FIB-4 index ≥1.3. Receiver operating characteristic analysis revealed that cFT <7.62 ng/dL (area under the curve [AUC] = 0.639) and SHBG ≥49.8 nmol/L (AUC = 0.649) were the strongest risk factors for FIB-4 index ≥1.3. In contrast to previous findings showing low SHBG concentrations in NAFLD, we provide evidence that high SHBG and low bioactive testosterone are associated with liver fibrosis.

Entities:  

Keywords:  Fibrosis-4 index; Liver fibrosis; Non-alcoholic fatty liver disease; Sex hormone-binding globulin; Testosterone

Mesh:

Substances:

Year:  2019        PMID: 31068503     DOI: 10.1507/endocrj.EJ18-0505

Source DB:  PubMed          Journal:  Endocr J        ISSN: 0918-8959            Impact factor:   2.349


  6 in total

1.  Relationship between total testosterone, sex hormone-binding globulin levels and the severity of non-alcoholic fatty liver disease in males: a meta-analysis.

Authors:  Man-Qiu Mo; Zi-Chun Huang; Zhen-Hua Yang; Yun-Hua Liao; Ning Xia; Ling Pan
Journal:  Ther Adv Endocrinol Metab       Date:  2022-06-24       Impact factor: 4.435

2.  Low Testosterone Is Associated With Nonalcoholic Steatohepatitis and Fibrosis Severity in Men.

Authors:  Monika Sarkar; Katherine Yates; Ayako Suzuki; Joel Lavine; Ryan Gill; Toni Ziegler; Norah Terrault; Sandeep Dhindsa
Journal:  Clin Gastroenterol Hepatol       Date:  2019-12-05       Impact factor: 11.382

Review 3.  Uric acid participating in female reproductive disorders: a review.

Authors:  Junhao Hu; Wenyi Xu; Haiyan Yang; Liangshan Mu
Journal:  Reprod Biol Endocrinol       Date:  2021-04-27       Impact factor: 5.211

Review 4.  Characteristic Features of Nonalcoholic Fatty Liver Disease in Japan with a Focus on the Roles of Age, Sex and Body Mass Index.

Authors:  Maki Tobari; Etsuko Hashimoto
Journal:  Gut Liver       Date:  2020-09-15       Impact factor: 4.519

5.  FIB-4 index is a marker for a subsequent decrease in insulin secretion in a non-diabetic Japanese population.

Authors:  Tomoyuki Fujita; Makoto Daimon; Satoru Mizushiri; Yuki Nishiya; Hiroshi Murakami; Jutaro Tanabe; Yuki Matsuhashi; Miyuki Yanagimachi; Itoyo Tokuda; Kaori Sawada; Kazushige Ihara
Journal:  Sci Rep       Date:  2020-09-25       Impact factor: 4.379

6.  Hypogonadism and liver fibrosis in HIV-infected patients.

Authors:  E Quiros-Roldan; T Porcelli; L C Pezzaioli; M Degli Antoni; S Paghera; M Properzi; E Focà; C Carriero; F Castelli; A Ferlin
Journal:  J Endocrinol Invest       Date:  2021-01-29       Impact factor: 4.256

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.